Table 1.
Architectural changes in muscles from satellite-cell depleted and control mice
| Tamoxifen-Treated WT | Tamoxifen-Treated Pax7-DTA | Vehicle-Treated Pax7-DTA | |||||
|---|---|---|---|---|---|---|---|
| Casted | Uncasted | Casted | Uncasted | Casted | Uncasted | ||
| Soleus | Mass (g) | 9.11±3.65 | 10.8±2.46 | 9.03±2.55 | 10.9±2.27 | 7.90±294 | 9.02±2.19 |
| Raw Fiber Length (mm) | 8.87±1.06 | 7.43±1.41 | 7.83±1.41 | 6.85±1.36 | 8.74±1.13 | 6.97±0.46* | |
| PCSA (mm2) | 0.95±0.36 | 1.38±0.35* | 1.17±0.28 | 1.74±0.53* | 0.91±0.27 | 1.37±0.28* | |
| Sarcomere Length (μm) | 2.49±0.12+ | 2.49±0.33+ | 2.69±0.15 | 2.83±0.26 | 2.75±0.16 | 2.85±0.20 | |
| TA | Mass (g) | 23.1±5.92 | 37.3±4.52* | 25.2±9.35 | 37.2±7.63* | 25.1±5.50 | 37.5±6.47* |
| Raw Fiber Length (mm) | 6.22±0.79 | 7.56±1.04* | 6.33±0.90 | 7.21±0.76* | 5.98±0.62 | 7.04±0.74* | |
| PCSA (mm2) | 2.90±0.60 | 4.11±0.64* | 3.45±1.11 | 4.22±0.67 | 3.52±1.05 | 4.40±0.63 | |
| Sarcomere Length (μm) | 2.11±0.17+ | 2.23±0.26 | 2.35±0.23 | 2.22±0.20 | 2.22±0.12 | 2.23±0.21 | |
| EDL | Mass (g) | 6.29±1.25 | 9.33±1.09* | 5.96±2.27 | 8.00±1.64* | 6.95±1.04 | 8.67±1.13* |
| Raw Fiber Length (mm) | 5.52±0.87 | 7.03±1.33*+ | 4.80±0.50 | 5.64±0.95* | 5.82±0.81+ | 6.37±0.54 | |
| PCSA (mm2) | 1.06±0.29 | 1.25±0.22 | 1.16±0.44 | 1.41±0.35 | 1.26±0.27 | 1.44±0.22 | |
| Sarcomere Length (μm) | 2.48±0.29 | 2.48±0.15 | 2.51±0.27 | 2.61±0.20 | 2.78±0.39 | 2.83±0.28 | |
| Sarcomere Number | 2242±356+ | 2832±445*+ | 1922±192 | 2154±284 | 2159±212+ | 2265±236 | |
Values are listed as mean ± SD for tamoxifen-treated WT (N=7) and vehicle-treated Pax7-DTA groups (N=6), and for tamoxifen-treated Pax7-DTA group (N=10). For measurement of physiologic cross-sectional area (PCSA), raw fiber length was normalized to a resting sarcomere length of 2.5μm.
*
significant difference (P <0.05) between the casted limb and the uncasted limb.
+
significant difference (P <0.05) between the experimental and control groups.